APA (7th ed.) Citation

Brown, M. S., Goldin, J., Kim, G. H., Zhang, X., & Poole, L. Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: Subanalysis from two phase II trials of pamrevlumab. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Brown, Matthew S., Jonathan Goldin, Grace Hyun Kim, Xueping Zhang, and Lona Poole. Minimum Clinically Important Difference in Quantitative Lung Fibrosis Score Associated with All-cause Mortality in Idiopathic Pulmonary Fibrosis: Subanalysis from Two Phase II Trials of Pamrevlumab. BMJ Publishing Group.

MLA (9th ed.) Citation

Brown, Matthew S., et al. Minimum Clinically Important Difference in Quantitative Lung Fibrosis Score Associated with All-cause Mortality in Idiopathic Pulmonary Fibrosis: Subanalysis from Two Phase II Trials of Pamrevlumab. BMJ Publishing Group.